September 15th, 2014
Selections from Richard Lehman’s Literature Review: September 15th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include prehospital ticagrelor in STEMI, ivabradine in stable CAD without clinical HF, FFR-guided PCI for stable CAD, and more.
May 13th, 2014
A Second Darapladib Phase 3 Trial Misses Its Endpoint
Larry Husten, PHD
GSK said today that a large phase 3 trial of a once highly promising drug had failed to meet its primary endpoint. Last year the company announced that another phase 3 trial with the same drug had failed. GSK said it would “further analyse the data and better understand the findings” but that, for now at least, […]
May 8th, 2014
Selections from Richard Lehman’s Literature Review: May 8th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include darapladib for preventing ischemic events in stable CHD, the DAMASCENE analysis, a review of John Brush’s new book, and more.
November 12th, 2013
Promising GSK Heart Drug Misses Primary Endpoint in 15,000-Patient Trial
Larry Husten, PHD
GlaxoSmithKline announced today that the first of two pivotal phase 3 trials with a new drug, darapladib, had failed to meet its primary endpoint. Full results of the trial will be presented at a scientific meeting. The STABILITY trial (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) tested the effect of darapladib, an investigational Lp-PLA2 inhibitor, in more than […]
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?